ClinicalTrials.gg

Program

eculizumab

Also written as “Eculizumab”, “Eculizumab Injection” and “Soliris (eculizumab)”.

Its studies are mostly in Hemoglobinuria, Paroxysmal · Atypical Hemolytic Uremic Syndrome · Myasthenia Gravis · Neuromyelitis Optica · Guillain-Barre Syndrome, led by 4 companies.

Furthest: phase 4, since Mar 23, 200936 company-led studies, 1 open or runningNext primary completion: Dec 7, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca311 open or runningphase 4since Mar 23, 2009Jul 18, 2005Dec 7, 2026phase 3 · NCT06724809
AO GENERIUM20 open or runningphase 3since Jul 3, 2020Jul 3, 2020none ahead
Samsung Bioepis20 open or runningphase 3since Aug 12, 2019Oct 24, 2018none ahead
Biocad10 open or runningphase 3since May 16, 2025May 16, 2025none ahead

Also a collaborator on its studies: cmic-co-ltd-japan.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 21 studies since Jul 18, 2005.

  1. May 15, 2014Phase 3 study in Delayed Graft FunctionAstraZeneca · NCT02145182 · 288 enrolled · United States, Australia, Brazil and more
  2. Nov 22, 2014Phase 3 study in Myasthenia GravisAstraZeneca · NCT02301624 · 117 enrolled · United States, Argentina, Belgium and more
  3. Oct 24, 2018Samsung Bioepis's first study: phase 1 study in HealthyNew to Samsung BioepisSamsung Bioepis · NCT03722329 · 240 enrolled · Germany
  4. Nov 26, 2018Phase 3 study in Myasthenia GravisAstraZeneca · NCT03759366 · 12 enrolled · United States, Japan
  5. Aug 12, 2019Phase 3 study in Hemoglobinuria, ParoxysmalSamsung Bioepis · NCT04058158 · 50 enrolled · India, Korea, Republic of, Malaysia and more
  6. Nov 5, 2019Phase 3 study in Neuromyelitis OpticaAstraZeneca · NCT04155424 · 5 enrolled · United States, Canada, Germany and more
  7. Mar 23, 2020Phase 4 study in Hemoglobinuria, ParoxysmalAstraZeneca · NCT04320602 · 18 enrolled · United Kingdom
  8. Jul 3, 2020AO GENERIUM's first study: phase 3 study in Hemoglobinuria, ParoxysmalNew to AO GENERIUMAO GENERIUM · NCT04463056 · 32 enrolled · Russian Federation
  9. Nov 30, 2020Phase 3 study in Hemoglobinuria, ParoxysmalAO GENERIUM · NCT04679103 · 50 enrolled · Russian Federation
  10. Feb 9, 2021Phase 3 study in Guillain-Barre SyndromeAstraZeneca · NCT04752566 · 57 enrolled · Japan
  11. May 17, 20232 phase 3 studiesAstraZeneca · NCT05876351, NCT05886244
  12. Nov 19, 2024Phase 3 study in Neuromyelitis OpticaAstraZeneca · NCT06724809 · 21 enrolled · China
  13. Dec 11, 2024Phase 3 study in Myasthenia GravisAstraZeneca · NCT06764160 · 15 enrolled · China
  14. May 16, 2025Biocad's first study: phase 3 study in Hemoglobinuria, ParoxysmalNew to BiocadBiocad · NCT06987864 · 24 enrolled · Russian Federation

Ahead

  1. Dec 7, 2026Primary completion: phase 3 study in Neuromyelitis OpticaAstraZeneca · NCT06724809

TargetBeta

C5 →read by rule
“Complement C5 inhibitor”ChEMBL 37, by rule

Other programs on C5

ProgramCompanyFurthest phaseStudies
ravulizumabruleAstraZenecaphase 435
pozelimabruleRegeneron Pharmaceuticalsphase 414
zilucoplanruleUCBphase 314
vilobelimabruleinflarx-gmbhphase 313
CrovalimabruleHoffmann-La Rochephase 310
cemdisiranruleRegeneron Pharmaceuticalsphase 310
ABBV-6628AbbViephase 21

Studies

All 36 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06987864Hemoglobinuria, Paroxysmal · Russian Federation3CompletedBiocadNov 2, 202224
NCT06764160Myasthenia Gravis · China3CompletedAstraZenecaDec 29, 202515
NCT06724809Neuromyelitis Optica · China3Active, not recruitingAstraZenecaDec 7, 202621
NCT05886244Hemoglobinuria, Paroxysmal · China3CompletedAstraZenecaApr 14, 202525
NCT05876351Atypical Hemolytic Uremic · China3CompletedAstraZenecaMay 7, 202525
NCT04752566Guillain-Barre Syndrome · Japan3CompletedAstraZenecaAug 3, 202257
NCT04679103Hemoglobinuria, Paroxysmal · Russian Federation3CompletedAO GENERIUMApr 20, 202050
NCT04463056Hemoglobinuria, Paroxysmal · Russian Federation3CompletedAO GENERIUMOct 16, 201832
NCT04320602Hemoglobinuria, Paroxysmal · United Kingdom4CompletedAstraZenecaDec 20, 202218
NCT04155424Neuromyelitis Optica · United States, Canada, Germany and more3TerminatedAstraZenecaJul 31, 20235
NCT04058158Hemoglobinuria, Paroxysmal · India, Korea, Republic of, Malaysia and more3CompletedSamsung BioepisSep 21, 202150
NCT03759366Myasthenia Gravis · United States, Japan3CompletedAstraZenecaJan 6, 202212
NCT03722329Healthy · Germany1CompletedSamsung BioepisMar 29, 2019240
NCT02301624Myasthenia Gravis · United States, Argentina, Belgium and more3CompletedAstraZenecaJan 15, 2019117
NCT02145182Delayed Graft Function · United States, Australia, Brazil and more3CompletedAstraZenecaNov 22, 2016288
NCT02003144Neuromyelitis Optica · United States, Argentina, Australia and more3CompletedAstraZenecaJul 12, 2021119
NCT01997229Myasthenia Gravis · United States, Argentina, Australia and more3CompletedAstraZenecaFeb 2016125
NCT01892345Neuromyelitis Optica · United States, Argentina, Australia and more3TerminatedAstraZenecaJul 17, 2018143
NCT01757431Atypical Hemolytic Uremic Syndrome · Japan2CompletedAstraZenecaSep 24, 20132
NCT01567085Stage V Chronic Kidney Disease · Australia, France, Italy and more2CompletedAstraZenecaJun 11, 201580
NCT01410916Shiga-like Toxin-producing Escherichia Coli · Germany3CompletedAstraZenecaJan 2012198
NCT01399593Antibody Mediated Rejection · United States, Australia, France and more2TerminatedAstraZenecaMay 13, 2014102
NCT01194973Atypical Hemolytic Uremic Syndrome · United States, Belgium, France and more2CompletedAstraZenecaOct 201344
NCT01193348Atypical Hemolytic Uremic Syndrome · United States, Australia, Belgium and more2CompletedAstraZenecaJan 201422
NCT01194804Hemoglobinuria, Paroxysmal2CompletedAstraZenecaSep 201027
NCT01192399Hemoglobinuria, Paroxysmal2CompletedAstraZenecaJun 200829
NCT00867932Hemoglobinuria, Paroxysmal · United States4CompletedAstraZenecaMay 12, 20117
NCT00844844Atypical Hemolytic Uremic Syndrome · United States, Austria, France and more2CompletedAstraZenecaSep 20101
NCT00844545Atypical Hemolytic Uremic Syndrome · United States, Austria, France and more2CompletedAstraZenecaSep 201016
NCT00844428Atypical Hemolytic Uremic Syndrome · Canada, France, Germany and more2CompletedAstraZenecaOct 20105
NCT00838513Atypical Hemolytic Uremic Syndrome · Canada, France, Germany and more2CompletedAstraZenecaOct 201015
NCT00727194Myasthenia Gravis · United States, Canada, United Kingdom2TerminatedAstraZenecaMar 201114
NCT00485576Allergic Asthma · Canada2CompletedAstraZenecaSep 200821
NCT00122317Hemoglobinuria, Paroxysmal · United States, Australia, Belgium and more3CompletedAstraZenecaSep 2008187
NCT00122304Hemoglobinuria, Paroxysmal · United States, Australia, Belgium and more3CompletedAstraZeneca85
NCT00122330Hemoglobinuria, Paroxysmal · United States, Australia, Belgium and more3CompletedAstraZeneca75

How it is read

Names in the registry

  • “Eculizumab”, 23 entries
  • “eculizumab”, 10 entries
  • “Eculizumab Injection”, 1 entry
  • “Soliris (eculizumab)”, 1 entry
  • “Elizaria®”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.